Use of Myoinositol in Polycystic Ovary Syndrome

Myoinositol (MI) is a promising treatment for managing Polycystic Ovary Syndrome (PCOS), showing comparable efficacy to metformin with fewer side effects. Studies and meta-analyses involving thousands of participants have demonstrated MI's benefits in improving insulin sensitivity, reducing androgen levels, and enhancing ovulation and menstrual regularity. MI supplementation (2-4 g/day) lowers fasting insulin levels, improves hormonal balance, and increases ovulation rates, enhancing fertility outcomes. It also supports mental health by modulating serotonin pathways. The recommended dosage is 4 grams per day, typically over 3 to 6 months, and is generally safe with mild gastrointestinal side effects. Combination therapies with D-chiro-inositol, folic acid, and other supplements may offer additional benefits. While MI is increasingly recognized in clinical guidelines, further high-quality research is needed to optimize individualized patient care.